Zoetis Inc. (NYSE:ZTS) Shares Sold by Waycross Partners LLC

Waycross Partners LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 32.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,000 shares of the company’s stock after selling 4,800 shares during the period. Waycross Partners LLC’s holdings in Zoetis were worth $1,974,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Hartford Funds Management Co LLC acquired a new stake in Zoetis in the 4th quarter worth about $292,000. Savant Capital LLC boosted its holdings in Zoetis by 9.0% in the 4th quarter. Savant Capital LLC now owns 8,002 shares of the company’s stock worth $1,579,000 after buying an additional 660 shares during the last quarter. Alpha Cubed Investments LLC boosted its holdings in Zoetis by 17.6% in the 4th quarter. Alpha Cubed Investments LLC now owns 118,162 shares of the company’s stock worth $23,322,000 after buying an additional 17,708 shares during the last quarter. MONECO Advisors LLC acquired a new stake in Zoetis in the 4th quarter worth about $200,000. Finally, Brighton Jones LLC boosted its holdings in Zoetis by 12.4% in the 4th quarter. Brighton Jones LLC now owns 3,127 shares of the company’s stock worth $617,000 after buying an additional 344 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ZTS. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. The Goldman Sachs Group boosted their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Piper Sandler restated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Barclays lowered their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Finally, Stifel Nicolaus lowered their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis has an average rating of “Buy” and an average price target of $216.13.

Zoetis Trading Down 0.3 %

ZTS traded down $0.53 during trading hours on Tuesday, reaching $159.17. The company’s stock had a trading volume of 3,647,859 shares, compared to its average volume of 3,147,432. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market cap of $72.80 billion, a PE ratio of 31.39, a P/E/G ratio of 2.42 and a beta of 0.85. The business’s 50-day moving average is $170.66 and its 200-day moving average is $179.12. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same quarter in the prior year, the company posted $1.15 earnings per share. The company’s revenue was up 8.5% on a year-over-year basis. As a group, equities research analysts predict that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 1.09%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 2,209 shares of company stock valued at $371,293 over the last quarter. 0.16% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.